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The Ras/Raf/MAPK pathway is probably the best charac-terized signal transduction pathway in cell biology. The
function of this pathway is to transduce signals from the
extracellular milieu to the cell nucleus where specific genes
are activated for cell growth, division and differentiation. The
Ras/Raf/MAPK pathway is also involved in cell cycle regu-
lation, wound healing and tissue repair, integrin signaling and
cell migration.1–3 Finally, the Ras/Raf/MAPK pathway is able
to stimulate angiogenesis through changes in expression of
genes directly involved in the formation of new blood ves-
sels.4 Thus, signaling through the Ras/Raf/MAPK regulates a
variety of cellular functions that are important for tumorigen-
esis.
Dysregulation of this pathway is a common event in
cancer as Ras is the most frequently mutated oncogene in
human cancer. Mutations in the K-ras oncogene have been
localized in codons 12, 13, 59 and 61 with those at codons 12
and 61 occurring most frequently. K-ras mutations are
present in 15-50% of lung cancers and in 72–90% of pancre-
atic cancers.5,6 Even in the absence of activating mutations,
K-ras still plays a role in oncogenesis via Ras gene amplifi-
cation, overexpression or upstream activation of the pathway.
Each of these potential cellular alterations will produce in-
creased activation of Ras effectors, thereby promoting devel-
opment of tumors. For example, 40% of esophageal cancers
have amplification of the K-ras gene7 and in approximately
50% of breast cancers, Ras is highly active in association
with expression of HER-2/Neu receptors.8 Mutations in other
members of the pathway are also common in other forms of
cancers. Somatic B-raf mutations have been found in 60-70%
of malignant melanomas and are also seen in papillary thy-
roid cancer, colon and ovarian cancers.9 Furthermore, activa-
tion of MAPK –not associated with either K-ras or BRAF
activating mutations are seen in 41% of low-grade ovarian
serous carcinomas.10
The ras superfamily of genes encodes small GTP-
binding proteins that are responsible for regulation of many
cellular processes, including differentiation, cytoskeletal or-
ganization, and protein trafficking.11 Oncogenic ras genes in
human cells include H-ras, N-ras and K-ras.12 The 21-kd
transforming proteins H- and K- ras genes were first identi-
fied as the counterparts of the oncogenes of the Harvey and
Kirsten rat sarcoma viruses, whereas the N-ras oncogene was
isolated from a neuroblastoma and has not been found in any
retroviruses.12 Since mutations in K-ras and not in H-ras or
N-ras are common in lung cancer, this review will focus on
K-ras. K-ras is initially synthesized as an inactive cytosolic
pro-peptide. Then the protein undergoes a series of post-
translational modifications at its carboxyl terminus that in-
crease its hydrophobicity allowing its localization to the
lipid-rich cell membrane.13 An important post-translational
modification is farnesylation in the hydrophobic tail of the
carboxyl terminal group. This reaction is catalyzed by the
enzyme farnesyltransferase which adds a 15-carbon hydro-
bobic farnesyl isoprenyl to the carboxyl terminus of Ras.
Once in the cell membrane, K-ras cycles between inactive
guanosine diphosphate–bound and active guanosine triphos-
phate (GTP) –bound states, thereby activating a series of
effector kinases –such as Raf and MAPK- that phosphorylate
a cascade of signaling proteins.14 The principal consequence
of the mutated proteins is a marked decrease in interactions
between Ras and its GTPase activator protein.15 Instead of
reverting to its inactive guanosine diphosphate–bound state,
the modified conformation of mutant Ras favors its active
GTP-bound state, which has a higher propensity to activate
downstream effectors even in the absence of growth factor
stimulation, conferring a proliferative advantage to tumors.
Activation of the pathway begins when a signal binds to
a protein tyrosine kinase receptor. The epidermic growth
factor receptor (EGFR) and the platelet-derived growth factor
receptor (PDGFR) are the best-known receptors in the path-
way. However, multiple upstream receptors including other
receptor tyrosine kinases, integrins, serpentine receptors, het-
erotrimeric G-proteins and cytokine receptors are able to
activate K-ras.16 Binding of a ligand to EGF receptor induces
oligomerization of the receptor, a process that results in
juxtaposition of the cytoplasmic, catalytic domains in a man-
ner that allows activation of the kinase activity and transphos-
phorylation.17 Adaptor proteins such as Grb2 are now able to
recognize sequence homology 2 (SH2) domains such as Shc,
which in turn, recruit guanine nucleotide exchange factors
(GEFs) like SOS-1 or CDC25 to the cell membrane17 (figure
1). The GEF becomes capable of interacting with Ras pro-
teins at the cell membrane to promote a conformational
change and the exchange of GDP for GTP. Following Ras
activation, Raf is recruited to the cell membrane through
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binding to the switch I domain of Ras and also by lipid
binding.18
Raf is the best characterized Ras effector and is a
member of a family of serine/threonine kinases, that includes
Raf-1, A-Raf and B-Raf. Raf activation stimulates a signaling
cascade by phosphorylation of MAPK which successively
phosphorylate and activate downstream proteins such as
ERK1 and ERK2 (figure 1). Activation of ERK is critical for
a large number of Ras-induced cellular responses. ERK1 and
ERK2 phosphorylate and activate a variety of nuclear tran-
scription factors and kinases, including Elk-1, c-Ets1, c-Ets2,
p90RSK1, MNK1, MNK2, as well as other proteins such as
the anti-proliferative protein Tob (figure 1). Many of these
MAPK/ERK targets have been implicated in Ras induced cell
transformation.14
MAPK, which in mammalians is also called MEK, is a
serine/threonine kinase activated in response to multiple sig-
nals including growth factors and cytokines to promote cell
survival and apoptosis through a number of mediators such as
JNK, SAPK, 14-3-3 and NF-KB19 (figure 1). MAPK may
also regulate both Raf and ERK, providing for cross talk
between multiple signaling pathways. Indeed, MAPK appears
to induce apoptosis by dysregulation of a number of pathways
including ERK, JNK and p38.20 MAPK has been shown to
directly interact with K-ras in a GTP-dependent manner.19,20
Raf and MAPK are not the only downstream targets of
K-ras, other downstream effectors of K-ras include the PI3K
cell survival pathway, the small GTP-binding proteins Rac
and Rho, and the stress-activated protein kinase pathway
(also referred to as the c-jun N-terminal kinase (JNK) path-
way).19 In addition, in response to cellular stress and cytokine
stimulation mediated through K-ras, the dual-specificity
p38MAPK kinases (MKK3 and MKK6) and the JNK kinases
(MKK4 and MKK7) phosphorylate p38MAPK and JNK, re-
spectively.20
Numerous studies have been performed evaluating the
prognostic importance of oncogenic ras mutations in human
tumors. Results to date have been conflicting in non-small
cell lung cancer, while some studies are negative or equivocal
in non-small cell lung cancer.21,22 However, the majority of
data favors K-ras mutations as being a negative prognostic
factor.23,24 Possible explanations for the inconsistent results
include the predominantly retrospective nature of these stud-
ies, the small numbers of patients studied, and the inability to
correct for other confounding prognostic factors. Further-
FIGURE 1. Ras/Raf/MAPK pathway
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more, activating K-ras mutations have been shown to dimin-
ish responsiveness to EGRF inhibitors.25
As Ras/Raf/MAPK signaling is complex, there are
many steps at which to target therapies designed to interfere
with signaling. Targeting the Ras/Raf/MAPK pathway could
be achieved by:
1. Inhibiting Ras protein expression, [antisense Ras
DNA, adenovirus expressing antisense K-ras and small inter-
ference RNA (siRNAs)].
2. Inhibiting membrane localization through post-trans-
lational modification or trafficking, [Farnesyltransferase in-
hibitors (FTIs and geranylgeranyltransferase inhibitors)].
3. Blocking Ras interaction with GEF and enhancing
Ras/GAP interactions.
4. Targeting oncogenic K-ras, (immunological thera-
pies against mutant K-ras and yeast expressing systems).
5. Inhibiting downstream targets of K-ras such as Raf
and MEK, (Raf kinase inhibitor-BAY 43-9006 and MEK
inhibitors such as CI-1040, PD0325901 and ARRY-142886)
Phase I and phase II clinical trials testing these ap-
proaches are currently ongoing.
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